Effectiveness, satisfaction and compliance with imiquimod in the treatment of external anogenital warts.
This study aims to evaluate the effectiveness of imiquimod treatment of external anogenital warts and analyse its possible relationship with patient treatment satisfaction and compliance under conditions of routine clinical practice. An observational, prospective and multi-centre study was conducted in a cohort of 559 patients with external anogenital warts. Imiquimod 5% cream was administered three times a week until the end of treatment (complete wart clearance or up to a maximum of 16 weeks). Effectiveness and compliance were evaluated at four weeks and again at the end of treatment, when satisfaction was also assessed. Complete wart clearance was experienced by 66.6% of patients at the end of treatment and a 50% or greater reduction in total wart area occurred in 79.5%. Imiquimod was more effective in patients who were more satisfied and compliant with treatment. Under conditions of routine clinical practice, imiquimod is an effective treatment for external anogenital warts.
Vilata
Juan-José
JJ
Departamento de Dermatología, Hospital General Universitario, Valencia, Spain.
Badia
Xavier
X
D000328:Adult; D000634:Aminoquinolines / Q000627:therapeutic use*; D003218:Condylomata Acuminata / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers; D008297:Male; D009824:Ointments / Q000008:administration & dosage; D010349:Patient Compliance; D011446:Prospective Studies; D016896:Treatment Outcome; D014622:Vaginal Creams, Foams, and Jellies
D000634:Aminoquinolines; D007369:Interferon Inducers; D009824:Ointments; D014622:Vaginal Creams, Foams, and Jellies; D000077271:Imiquimod